Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ondansetron oral spray - Arovella Therapeutics

Next Previous
X
Search
Drug Profile

Ondansetron oral spray - Arovella Therapeutics

Alternative Names: Ondansetron lingual spray; Ondansetron OS; Ondansetron succinate oro-mucosal spray - Arovella Therapeutics; SUD-002; SUDA-002; Zensana; ZondaMist

Latest Information Update: 31 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NovaDel Pharma
  • Developer Arovella Therapeutics
  • Class Anti-inflammatories; Antiemetics; Antipsychotics; Carbazoles; Drug withdrawal therapies; Imidazoles; Irritable bowel syndrome therapies; Obesity therapies; Small molecules; Smoking cessation therapies
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting; Radiotherapy-induced nausea and vomiting

Most Recent Events

  • 28 Dec 2020 No recent reports of development identified for clinical-Phase-Unknown development in Chemotherapy-induced-nausea-and-vomiting(Prevention) in USA (Transmucosal, Spray)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Chemotherapy-induced-nausea-and-vomiting(Prevention) in USA (Transmucosal, Spray)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Postoperative-nausea-and-vomiting(Prevention) in USA (Transmucosal, Spray)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top